Orthotopic liver transplantation (OLT) in patients with end-stage liver disease is a procedure associated with high cardiac output, low systemic vascular resistance (SVR), coagulopathy and the potential for significant blood loss. A feature of hypertrophic obstructive cardiomyopathy (HOCM) is left ventricular outflow tract obstruction which may be exacerbated by reduced SVR, reduced filling pressures, tachycardia and positive inotropy. We report two cases of OLT in patients with HOCM. Case reports
Case reports
CASE NO. 1 The patient was a 46-yr-old male with end-stage alcoholic liver disease. He had portal hypertension with severe ascites, oesophageal varices and impaired renal function. Clotting function tests showed mild coagulopathy (international normalized ratio (INR) 1.5). Preoperative transoesophageal echocardiography (TOE) was performed to evaluate a murmur heard on physical examination. It showed asymmetrical septal hypertrophy, systolic anterior motion (SAM) of the mitral valve with normal mitral morphology, mild mitral regurgitation (MR) and left ventricular outflow tract (LVOT) obstruction, and a resting gradient 36 mm Hg ( fig. 1 ) and thus a diagnosis of hypertrophic obstructive cardiomyopathy (HOCM) was made. After nitrate provocation there was increased SAM, severe MR and an LVOT gradient of 64 mm Hg.
Anaesthesia was induced with fentanyl 6 g kg 91 and thiopentone 100 mg and maintained with fentanyl 3 g kg 91 h 91 and halothane in air and oxygen. Neuromuscular block was produced with vecuronium. Monitoring included an oximetric pulmonary artery catheter and TOE. During liver resection a baseline TOE was performed and fluid challenges were given to assess changes in left ventricular (LV) dimensions. Full cardiopulmonary bypass with heparin-bonded tubing was on standby.
Haemodynamic variables at various times are shown in table 1.
During the anhepatic stage the patient developed a low systemic vascular resistance index (SVRI) and increased cardiac index (CI). Fibrinolysis was demonstrated by a decrease in euglobulin clot lysis time and fibrinogen concentration, and 7 litre of blood were lost over 120 min. An infusion of phenylephrine was commenced and fluid was replaced according to LV dimensions on TOE rather than pulmonary capillary wedge pressure (PCWP). Veno-venous bypass (femoro-portal to axillary vein) was used electively during the anastomosis of the new liver.
On reperfusion the patient developed severe reperfusion syndrome. He also developed a severe coagulopathy and another 15 litre of blood was lost in the first hour after reperfusion. Total intraoperative blood loss was 42 litre. Vasodilatation and blood loss were associated with an increase in the severity of the LVOT obstruction measured on TOE. TOE also showed a relatively empty LV with dynamic systolic function (in spite of a PCWP of 30 mm Hg), increased SAM, severe LVOT obstruction (maximum measured gradient 120 mm Hg) and severe MR. This was treated with aggressive volume replacement and infusion of phenylephrine. Inotropes were avoided.
In the 3 h after reperfusion the degree of outflow obstruction reduced gradually as SVRI increased. His postoperative course was relatively uneventful and he was well 18 months after transplant. . Transoesophageal echocardiography showed development of marked SAM with severe MR and LV cavity obliteration during systole ( fig. 2) The maximal LVOT gradient measured was 64 mm Hg. Multiple boluses and increasing rates of infusion of phenylephrine were administered. Washed donor red cells (600 ml) and Haemaccel 1 litre were infused in the first 30 min after reperfusion, despite minimal blood loss, in an attempt to increase ventricular volumes and reduce LV systolic obliteration as seen on TOE. PCWP increased to 24 mm Hg and CI increased to 10.61 min 91 m 92 but LV obliteration and outflow tract obstruction changed little. Slowly over 2 h LVOT obstruction and MR and SAM resolved to levels similar to those in the preanhepatic stage. One hour after reperfusion an infusion of prostaglandin E1 (PGE1) 10 g h 91 was started, slowly increasing to 30 g h 91 as the patient's vasodilatation allowed.
The patient's postoperative course was complicated only by minor sepsis and transient pancytopenia. She was well 1 yr after transplant and her hepato-pulmonary syndrome is resolving.
Discussion
Hypertrophic cardiomyopathy (HCM) is inappropriate myocardial hypertrophy often involving the septum of a non-dilated left ventricle. HOCM is a subset of HCM in which the hypertrophy causes LVOT obstruction. It is an autosomal dominant condition with variable penetrance. 1 The features of HOCM are a hypercontractile left ventricle, diastolic dysfunction, a high ejection fraction and systolic anterior motion of the mitral valve with or without mitral regurgitation. The obstruction is dynamic in that it changes depending on preload, afterload, sympathetic activity and posture.
The symptoms of HOCM range from none to dyspnoea, syncope, palpitations, chest pain and sudden death. Signs include a jerky pulse, fourth heart sound and an early to mid-systolic murmur increasing with a Valsalva manoeuvre. Diagnosis is usually confirmed by echocardiography.
The problems of providing anaesthesia to a patient with HOCM are exacerbated in liver transplantation. Patients with liver disease tend to have a low systemic vascular resistance and liver transplantation is associated with further vasodilatation, the potential for significant blood loss and occasionally the need for inotropes around the time of reperfusion. All of these factors exacerbate the haemodynamic disturbances of HOCM, which benefits from high afterload and preload, a relatively low heart rate and negative inotropy. Diastolic function is markedly impaired in HOCM and delayed isovolumetric relaxation reduces early diastolic filling. 2 3 There is an increased reliance on atrial contraction, diastolic filling pressures and adequate duration of diastolic filling. 4 We chose an anaesthetic technique that avoided drugs such as isoflurane and pancuronium which cause vasodilatation and tachycardia and instead used halothane and vecuronium. We used phenylephrine for vasoconstriction as it has no inotropic or chronotropic effect. Our unit routinely administers PGE1 to all liver transplant patients in the postreperfusion period to increase hepatic blood flow and for its presumed cytoprotective effect. In case No. 1 we were unable to begin PGE1 infusion, a potent vasodilator, until the patient had returned to the ICU, because of his extreme peripheral vasodilatation. In case No. 2 the patient tolerated only a very slow increase in the infusion rate to 30 g h 91 in theatre.
Transoesophageal echocardiography played a very important role in the intraoperative management of both patients. The measured haemodynamics of high PCWP and low mean arterial pressure, especially in the post-reperfusion period, may have prompted the use of inotropic agents with their potentially deleterious effects. However, TOE demonstrated low ventricular volumes despite a high PCWP and management was therefore with additional fluids and a direct acting vasopressor (phenylephrine). It has been shown during OLT that TOE has a better correlation with ventricular volumes than does PCWP. [5] [6] [7] [8] In this case we found TOE to be the most useful guide to fluid management, especially in the post-reperfusion period.
